Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Algeta Signs Exclusive License Agreement with Lumiphore, Inc.

Published: Thursday, May 02, 2013
Last Updated: Thursday, May 02, 2013
Bookmark and Share
Algeta ASA has exercised its option to take an exclusive, worldwide license to patented Lumi4® bi-functional chelator technology from Lumiphore, Inc.

These technologies are currently being developed by Algeta to conjugate thorium-227 to tumor-targeting molecules to create Targeted Thorium Conjugates (TTCs).

Lumiphore’s Lumi4® technology is based on a unique class of bi-functional chelators that forms a novel cage structure surrounding and tightly binding thorium-227, which can then be covalently attached to a range of tumor-targeting molecules, such as monoclonal antibodies, to create potential cancer therapeutics. Algeta originally signed an option/license agreement with Lumiphore around this technology in 2010 and subsequently extended it to enable further evaluation to be conducted. This stage of evaluation has now been completed successfully.

In parallel with this license agreement, Algeta has also been granted a license by Lumiphore covering a second class of bi-functional chelators that bind strongly to thorium-227, with the option of including a further selection of compounds within that license if future exploratory work confirms their promise.

Under the terms of the agreements, Algeta will pay Lumiphore the option exercise fee for the Lumi4® chelators, and a signature and option fee for the second class of chelators, plus development and sales milestones and a royalty on product sales. Further financial details have not been disclosed.

Thomas Ramdahl, Algeta’s Chief Technology Officer, said: “Algeta is assembling a broad portfolio of proprietary technologies (including bi-functional chelators, linkers and tumor-targeting molecules), intellectual property and expertise as a platform for generating Targeted Thorium Conjugates, or TTCs. The addition of the Lumiphore technologies to the portfolio through this license and further option agreements will ensure that we have access to the best bi-functional chelators for thorium-227 as we seek to create a pipeline of TTCs designed to address multiple high-value opportunities in targeted cancer therapy.”

Algeta’s TTC strategy is based on gaining access to carefully selected tumor-targeting molecules, via in-licensing, collaboration or via third parties, to which it links thorium-227 thereby creating potential new therapeutics. Algeta’s disclosed TTC programs include collaborations with Sanofi and Ablynx; programs based on CD22- (hematological cancer) and HER2-targeting (breast/ovarian cancer) molecules in-licensed from Immunomedics and Affibody, respectively; and a fully owned TTC program targeting hematological cancers. Algeta is advancing its preclinical pipeline with the aim of entering its first TTC into clinical trials in 2014.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Flu Vaccine May Reduce Death Risk of Type 2 Diabetes
New research suggests that a new flu vaccine may reduce probability of type 2 diabetes patients being hospitalised with stroke and heart failure.
Gut Bacteria Older than Human Species
Some bacteria have lived in the human gut since before we were human, suggesting evolution could have a larger role inhuman bacterial makeup.
Evidence of Mosquito Transmitting Zika
A direct link between the Yellow fever mosquito and Zika transmission has been found following investigation into selective mosquito control.
Antibody-Based Drug for Multiple Sclerosis
New antibody-based drug paves the way for new strategies for controlling and treating multiple sclerosis.
Three-Drug Combinations Counter Antibiotic Resistance
Research shows that combinations of three different antibiotics can treat resistant bacteria, even if they are ineffective independently.
Mapping Zika’s Routes to Developing Fetus
UC researchers show how Zika virus travels from a pregnant woman to her fetus, and also identified a drug that could stop it.
Treating HIV with Cancer-Fighting Gene Shows Promise
A type of gene immunotherapy that has shown promising results against cancer could also be used against HIV.
Protein Teams Activate T-Cells
Caltech researchers have discovered T-cell genetic switching is controlled by four proteins acting in a multi-tiered fashion.
'Antigen-Presenting Cell' Defends Against Cancer
Through advanced imaging, researchers have identified cells that encourages increases in immune system cancer defences.
Zika Epidemic Likely to End Within Three Years
A team of scientists has predicted that the current Zika epidemic is likely to end within three years because there will be too few people left to infect.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!